RCT: Mirtazapine not better than placebo for the treatment of agitation in people with dementia and was possibly associated with increased mortality (7 vs.1 deaths, difference not statistically significant; p=0·065).

Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial – The Lancet

Commentary: Common antidepressant should no longer be used to treat people with dementia – University of Exeter